Key Highlights
- XORTX Therapeutics shares closed up 16% at $1.92.
- The company intends to file an Investigational New Drug application for XRx-026 in the fourth quarter of 2026.
- XRx-026 uses the company's novel XORLO oxypurinol formulation for gout.
- The U.S. market potential is estimated above $700 million annually.
XORTX Therapeutics Inc. (NASDAQ: XRTX) shares closed up 16% at $1.92 after the company announced it intends to file an Investigational New Drug application for its gout asset XRx-026 in the fourth quarter of 2026.
Company Overview
XORTX Therapeutics is a clinical-stage pharmaceutical company focused on developing therapies for kidney diseases and metabolic disorders linked to elevated uric acid levels, including gout and chronic kidney disease. The company's pipeline is built around xanthine oxidase inhibitor technology, targeting the enzyme responsible for uric acid production in the body.
XRx-026 utilizes the company's novel XORLO oxypurinol formulation, an approach intended to improve upon existing uric acid-lowering therapies used to manage gout, a condition caused by the buildup of uric acid crystals in joints that can lead to painful inflammatory flares if not adequately controlled.
What Happened
The company is progressing its novel XORLO oxypurinol formulation into a two-stage clinical trial designed to underpin a future New Drug Application. Pending necessary Capital and trial progress, the company envisions submitting the NDA within roughly 12 months, targeting a U.S. market potential estimated above $700 million annually.
Market Reaction
Shares rose sharply as investors responded to the clarity provided by the disclosed IND filing timeline and the scale of the targeted U.S. market opportunity for XRx-026.
Outlook
The planned fourth-quarter 2026 IND filing, followed by the two-stage clinical trial and a targeted NDA submission within roughly 12 months thereafter, represent the next major disclosed milestones for XRx-026, contingent on the company securing necessary capital.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...